{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:13:49Z","timestamp":1790871229437,"version":"4.1.0"},"reference-count":49,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2008,7,15]],"date-time":"2008-07-15T00:00:00Z","timestamp":1216080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The FEBS Journal"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:p>The neonatal Fc receptor (FcRn) is a major histocompatibility complex class I\u2010related molecule that regulates the half\u2010life of IgG and albumin. In addition, FcRn directs the transport of IgG across both mucosal epithelium and placenta and also enhances phagocytosis in neutrophils. This new knowledge gives incentives for the design of IgG and albumin\u2010based diagnostics and therapeutics. To study FcRn <jats:italic>in\u2003vitro<\/jats:italic> and to select and characterize FcRn binders, large quantities of soluble human FcRn are needed. In this report, we explored the impact of two free cysteine residues (C48 and C251) of the FcRn heavy chain on the overall structure and function of soluble human FcRn and described an improved bacterial production strategy based on removal of these residues, yielding \u223c\u200370\u2003mg\u00b7L<jats:sup>\u22121<\/jats:sup> of fermentation of refolded soluble human FcRn. The structural and functional integrity was proved by CD, surface plasmon resonance and MALDI\u2010TOF peptide mapping analyses. The strategy may generally be translated to the large\u2010scale production of other major histocompatibility complex class I\u2010related molecules with nonfunctional unpaired cysteine residues. Furthermore, the anti\u2010FcRn response in goats immunized with the FcRn heavy chain alone was analyzed following affinity purification on heavy chain\u2010coupled Sepharose. Importantly, purified antibodies blocked the binding of both ligands to soluble human FcRn and were thus directed to both binding sites. This implies that the FcRn heavy chain, without prior assembly with human \u03b22\u2010microglobulin, contains the relevant epitopes found in soluble human FcRn, and is therefore sufficient to obtain binders to either ligand\u2010binding site. This finding will greatly facilitate the selection and characterization of such binders.<\/jats:p>","DOI":"10.1111\/j.1742-4658.2008.06551.x","type":"journal-article","created":{"date-parts":[[2008,7,15]],"date-time":"2008-07-15T10:56:00Z","timestamp":1216119360000},"page":"4097-4110","source":"Crossref","is-referenced-by-count":31,"title":["Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues"],"prefix":"10.1111","volume":"275","author":[{"given":"Jan T.","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sune","family":"Justesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Fleckenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje E.","family":"Michaelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f8ril","family":"Berntzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania E.","family":"Kenanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muluneh B.","family":"Daba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vigdis","family":"Lauvrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Buus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Sandlie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,28]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2006.05.004"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830260327"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/372379a0"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi000749m"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.1955.0068"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018853506830"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199903)29:03<733::AID-IMMU733>3.0.CO;2-C"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.157.8.3317"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606304103"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0403235101"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI6968"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020400"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh896"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.7.4580"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.5.3266"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-024539"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830240308"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636556"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C300470200"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.1.346"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxl110"},{"key":"e_1_2_7_24_2","first-page":"355","article-title":"Single amino acid substitution in the Fc region of chimeric TNT\u20103 antibody accelerates clearance and improves immunoscintigraphy of solid tumors","volume":"41","author":"Hornick JL","year":"2000","journal-title":"J Nucl Med"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.622.65.2"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0454"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020917732218"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02644-4"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.7.3528"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1364"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1143"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1110\/ps.0233003"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(2001010)31:10<2986::AID-IMMU2986>3.0.CO;2-R"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2007.11.003"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2005.01.002"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/372336a0"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.2.638"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/13.8.993"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2004.11.014"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi052628y"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/13.12.1551"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzg088"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(02)00626-5"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M604292200"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0797-637"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1127"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2003.08.007"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.5.1.111"},{"key":"e_1_2_7_49_2","first-page":"153","article-title":"DARPins: a true alternative to antibodies","volume":"10","author":"Stumpp MT","year":"2007","journal-title":"Curr Opin Drug Discov Devel"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.119.3.1084"}],"container-title":["The FEBS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-4658.2008.06551.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1742-4658.2008.06551.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T01:48:49Z","timestamp":1698716929000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-4658.2008.06551.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,28]]},"references-count":49,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1111\/j.1742-4658.2008.06551.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1742-4658.2008.06551.x","archive":["Portico"],"relation":{},"ISSN":["1742-464X","1742-4658"],"issn-type":[{"value":"1742-464X","type":"print"},{"value":"1742-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,28]]}}}